Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 160
- Registration Number
- NCT06561685
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸University of Colorado Health Hospital, Aurora, Colorado, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
A Study of LY3532226 in Participants With Obesity
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT06557356
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology Pte. Ltd., Singapore, Singapore
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06538116
- Locations
- 🇯🇵
Inage Neurology and Memory Clinic, Inage, Chiba, Japan
🇯🇵Mental Clinic Sakurazaka, Fukuoka-shi, Fukuoka-Ken, Japan
🇯🇵Himeji Central Hospital Affiliated Clinic, Himeji, Hyogo, Japan
A Study of Subcutaneous Injection in Healthy Participants
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT06516913
- Locations
- 🇺🇸
Fortrea CRU, Inc., Dallas, Texas, United States
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 484
- Registration Number
- NCT06475729
- Locations
- 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 220
- Registration Number
- NCT06465069
- Locations
- 🇬🇧
St Bartholomew's Hospital, West Smithfield, London, United Kingdom
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT06444165
- Locations
- 🇺🇸
Concentrics Research, Indianapolis, Indiana, United States
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 508
- Registration Number
- NCT06440980
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06439277
- Locations
- 🇺🇸
Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology, Sacramento, California, United States
🇨🇦Premier Clinical Trial Network, Hamilton, Ontario, Canada
🇬🇧Bristol Royal Hospital for Children, Bristol, Bristol, City Of, United Kingdom
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT06413706
- Locations
- 🇧🇪
Centre Hospitalier Regional de la Citadelle, Liege, Belgium
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States